Who
Seth Lederman
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Tonix Pharmaceuticals Holding.
In numbers
- Trades disclosed
- 100
- Buys
- 45
- Sells
- 0
- Bought
- $1.7M
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Feb 2013
- Last trade
- 27 Aug 2026
- Last filed
- 31 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Aug 2026filed 31 Aug 2026 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Bought | $28K2,000 at $13.79 | filing |
| 27 Aug 2026filed 31 Aug 2026 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Bought | $28K2,000 at $13.79 | filing |
| 9 Jun 2026filed 9 Jun 2026 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Bought | $59K5,000 at $11.79 | filing |
| 9 Jun 2026filed 9 Jun 2026 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Bought | $59K5,000 at $11.79 | filing |
| 31 Mar 2026filed 1 Apr 2026 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Bought | $63K5,000 at $12.62 | filing |
| 31 Mar 2026filed 1 Apr 2026 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Bought | $63K5,000 at $12.62 | filing |
| 18 Mar 2026filed 18 Mar 2026 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Bought | $223K15,000 at $14.89 | filing |
| 18 Mar 2026filed 18 Mar 2026 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Bought | $223K15,000 at $14.89 | filing |
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —134,504 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —134,503 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —134,504 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —134,503 at $0.00 | filing |
| 15 May 2025filed 15 May 2025 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Bought | $86K4,000 at $21.55 | filing |
| 25 Feb 2025filed 27 Feb 2025 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —123,958 at $0.00 | filing |
| 25 Feb 2025filed 27 Feb 2025 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —123,958 at $0.00 | filing |
| 5 Feb 2025filed 27 Feb 2025 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code J | $185.18 at $3.38 | filing |
| 5 Feb 2025filed 27 Feb 2025 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code J | $10.22 at $3.30 | filing |
| 5 Feb 2025filed 27 Feb 2025 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code J | $01 at $0.15 | filing |
| 27 Feb 2024filed 6 Mar 2024 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —235,320 at $0.00 | filing |
| 27 Feb 2024filed 6 Mar 2024 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,903,680 at $0.00 | filing |
News
Tonix Pharmaceuticals (TNXP) Stock Price, News & AnalysisTNXP · 247wallst.com · 22 Oct 2026Tonix Pharmaceuticals Sets 2027 Phase 1 Target For TNX-801 Vaccine CandidateTNXP · rttnews.com · 15 Oct 2026Tonix Pharmaceuticals Begins Building Lyme Disease Drug Facility in Hamilton, MontanaTNXP · matr.net · 12 Oct 2026
0 headlines in the last 90 days name Seth Lederman; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.